tegoprazan

Tegoprazan is an orally active, highly selective gastric H+/K+-ATPase inhibitor that controls gastric acid secretion and motility, with an IC50 of 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPase in vitro.

Tegoprazan Benzoate is the benzoate salt form of Tegoprazan. Tegoprazan (CJ-12420) is a potassium-competitive acid blocker and serves as an effective, orally active, and highly selective inhibitor of gastric H+/K+-ATPase, which regulates gastric acid secretion and movement. Its IC50 values for pig, dog, and human H+/K+-ATPase in vitro are 0.29-0.52 μM.

(R)-Tegoprazan, a benzimidazole derivative, serves as a potent inhibitor of kidney H+/K+-ATPase, demonstrating significant efficacy with an IC50 of 98 nM against canine kidney Na+/K+-ATPase. This compound shows promise for research in gastrointestinal diseases.